|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
*
* From the Division of Pulmonary and Critical Care Medicine (Drs. Keane, Belperio, Burdick, and Strieter), UCLA School of Medicine, Los Angeles, CA.
Correspondence to: Michael P. Keane, MD, FCCP, Division of Pulmonary and Critical Care Medicine, UCLA School of Medicine 14-154 Warren Hall, 900 Veteran Ave, Los Angeles, CA 90095-1922.
Few
studies have addressed the importance of vascular remodeling in the
lung during the development of bleomycin-induced pulmonary fibrosis
(BPF). Lung-derived angiogenic activity is increased in
bleomycin-treated mice as compared to saline solution-treated control
mice. Moreover, we have shown that the CXC chemokines,
macrophage in inflammatory protein-2 and macrophage in inflammatory
protein-2 and interferon (IFN)-inducible protein 10 (IP-10), have an
important role in the pathogenesis of BPF that is mediated via the
regulation of angiogenesis. Interleukin (IL)-12 is a potent inducer of
IFN-
and hence the angiostatic CXC chemokines, IP-10 and monokine
induced by IFN-
(MIG). We postulated that interleukin (IL)-12
would attenuate BPF via inhibition of angiogenesis. To test this
hypothesis, we administered IL-12 or human serum albumin to
bleomycin-treated CBA/J mice, by daily intraperitoneal injection until
day 12. Mice treated with IL-12 demonstrated decreased hydroxyproline
levels as compared to human serum albumin-treated control mice
(24.2 ± 1.4 vs 30.8 ± 2.5; p < 0.05). Furthermore,
administration of IL-12 led to a time-dependent increase in lung
IFN-
, IP-10, and MIG. The antifibrotic effect of IL-12 could
be attenuated with simultaneous administration of neutralizing
anti-IFN-
antibodies. These findings support the notion that the
antifibrotic effects of IL-12 are mediated through IFN-
and
subsequently IP-10 and
MIG.
Footnotes
Abbreviations: BPF = bleomycin-induced pulmonary
fibrosis; IFN = interferon; IL = interleukin;
IP-10 = interferon-inducible 10 protein 10; MIG = monokine
induced by interferon-
Supported by National Institutes of Health grants HLO3906, P50HL56402, and P50HL6028.
Dr. Belperio is the recipient of a Glaxo Wellcome fellowship award.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |